Dana-Farber Cancer Institute's Dr. Pasi Jänne details FLAURA2 which found first-line osimertinib + platinum pemetrexed chemotherapy improved overall survival vs. monotherapy in EGFR mutated non-small cell lung cancer, including poorer prognosis patients.
The Flora 2 trial asked the question of adding chemotherapy to first-line ossamertinib treatment versus ossamertinib as therapy for newly diagnosed patients with advanced uh EGFR mutant lung cancer. EGFR lung cancers make up about a third of lung cancers worldwide. There's a global impact of the trial. And the study showed previously that the combination improved the progression for survival and now we have data um that it also improves overall survival. And, and, and what we'll show at ESO is that in patients with CNS metastasis, with uh concurrent P53 mutations or baseline detectable, circulating tumor DNA for an EGFR mutation. Things that are associated with a poor prognosis, the combination, patients treated with a combination have a better outcome in terms of survival than those treated with single agent uh awesomer. I, I, I think this is a uh significant step forward. This, this is the longest overall survival in this patient population that we've seen in any clinical trial to date. Um, and, uh, really shows that combination therapies can lead to improvements over a single agent, even, even over a single agent, very effective drug like ossamerini. I don't think this will be the last combination that will be developed. I think there's opportunity to. Use this as a platform to develop additional combination therapies, either enhancing chemotherapy awesomer or novel ways of enhancing awesomernip efficacy.
Related Presenters
